Rupert P. Austin

2.4k total citations
29 papers, 1.8k citations indexed

About

Rupert P. Austin is a scholar working on Molecular Biology, Spectroscopy and Organic Chemistry. According to data from OpenAlex, Rupert P. Austin has authored 29 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Spectroscopy and 8 papers in Organic Chemistry. Recurrent topics in Rupert P. Austin's work include Pharmacogenetics and Drug Metabolism (7 papers), Analytical Chemistry and Chromatography (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Rupert P. Austin is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Analytical Chemistry and Chromatography (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Rupert P. Austin collaborates with scholars based in United Kingdom, Singapore and Germany. Rupert P. Austin's co-authors include Patrick Barton, Robert J. Riley, Mark C. Wenlock, A. M. Davis, Dermot F. McGinnity, Paul D. Leeson, Scott L. Cockroft, Carol N. Manners, Michael H. Abraham and Roger V. Bonnert and has published in prestigious journals such as Chemical Communications, Journal of Medicinal Chemistry and Pharmaceutical Research.

In The Last Decade

Rupert P. Austin

29 papers receiving 1.7k citations

Peers

Countries citing papers authored by Rupert P. Austin

Since Specialization

Citations

This map shows the geographic impact of Rupert P. Austin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupert P. Austin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupert P. Austin more than expected).

Fields of papers citing papers by Rupert P. Austin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rupert P. Austin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupert P. Austin. The network helps show where Rupert P. Austin may publish in the future.

Co-authorship network of co-authors of Rupert P. Austin

This figure shows the co-authorship network connecting the top 25 collaborators of Rupert P. Austin. A scholar is included among the top collaborators of Rupert P. Austin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rupert P. Austin. Rupert P. Austin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction 2021 ·Clinical Pharmacokinetics ·(unknown), Dagmar Klein, (unknown), Joachim Grevel, Rupert P. Austin, Corina Becker, Lothar Roessig, Burkert Pieske, Dirk Garmann, Michaela Meyer	16
2	Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs 2016 ·Journal of Pharmaceutical Sciences ·(unknown), Rupert P. Austin, Peter M. Fischer, Jonathan Booth, Frank Gommer	5
3	Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists 2015 ·Bioorganic & Medicinal Chemistry Letters ·Rupert P. Austin, (unknown), Roger V. Bonnert, (unknown), Anthony R. Cook, Rhona J. Cox, (unknown), A. Gaw, Ken Grime, Premji Meghani, David Nicholls, (unknown), (unknown), John Steele, (unknown)	16
4	Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action 2012 ·Pulmonary Pharmacology & Therapeutics ·D.J. Nicholls, Shawn Jordan, Elaine Cadogan, Mandy Lawson, Rupert P. Austin, Stuart W. Paine, Philip Gardiner, Roger V. Bonnert, Stephen Connolly, Alan Young	3
5	Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Alessandro Schipani, Laura Dickinson, Marta Boffito, Rupert P. Austin, Andrew Owen, David Back, Saye Khoo, Geraint Davies	10
6	A Method for Measuring the Lipophilicity of Compounds in Mixtures of 10 2011 ·SLAS DISCOVERY ·Mark C. Wenlock, (unknown), Patrick Barton, Rupert P. Austin	54
7	The effect of ionized species on microsomal binding 2011 ·European Journal of Medicinal Chemistry ·Michael H. Abraham, Rupert P. Austin	44
8	A kinetic method for the determination of plasma protein binding of compounds unstable in plasma: Specific application to enalapril 2011 ·Journal of Pharmaceutical and Biomedical Analysis ·Mark C. Wenlock, Patrick Barton, Rupert P. Austin	8
9	AZD3199: A Potent And Selective Beta2-Adrenergic Receptor Agonist With Rapid Onset Of Action 2011 ·Alan Young, David Nicholls, Stephen Connolly, Elaine Cadogan, Roger V. Bonnert, (unknown), Mandy Lawson, Michael J. Stocks, (unknown), Stuart W. Paine, Rupert P. Austin, P. Jane Mutch, Philip Gardiner	1
10	SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction 2007 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Caroline A. Austin, Rupert P. Austin, Roger V. Bonnert, (unknown), (unknown), Mark Christie, Clare Dixon, Steven M. Hill, (unknown), Ian L. Martin, David Robinson, Paul Willis	24
11	Evaluation of Human Pharmacokinetics, Therapeutic Dose and Exposure Predictions Using Marketed Oral Drugs 2007 ·Current Drug Metabolism ·Dermot F. McGinnity, (unknown), Rupert P. Austin, Robert J. Riley	87
12	Evaluation of a series of bicyclic CXCR2 antagonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Iain A. S. Walters, Caroline A. Austin, Rupert P. Austin, Roger V. Bonnert, (unknown), Mark Christie, (unknown), (unknown), Caroline Grahames, Steven M. Hill, (unknown), (unknown), Shirley Lewis, Iain Martin, David Nicholls, David M. Robinson	52
13	A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES 2005 ·Drug Metabolism and Disposition ·Robert J. Riley, Dermot F. McGinnity, Rupert P. Austin	286
14	The Thermodynamics of the Partitioning of Ionizing Molecules Between Aqueous Buffers and Phospholipid Membranes 2005 ·Pharmaceutical Research ·Rupert P. Austin, Patrick Barton, A. M. Davis, (unknown), Mark C. Wenlock	26
15	THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES 2004 ·Drug Metabolism and Disposition ·Rupert P. Austin, Patrick Barton, (unknown), Robert J. Riley	140
16	The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical Properties 2002 ·Drug Metabolism and Disposition ·Rupert P. Austin, Patrick Barton, Scott L. Cockroft, Mark C. Wenlock, Robert J. Riley	320
17	Hydrolysis of a sulfonamide by a novel elimination mechanism generated by carbanion formation in the leaving group 2002 ·Chemical Communications ·J. Matthew Wood, (unknown), (unknown), Rupert P. Austin, Michael I. Page	12
18	Structure–reactivity relationships in the inactivation of elastase by β-sultams 2002 ·Organic & Biomolecular Chemistry ·(unknown), J. Matthew Wood, A. M. Davis, Rupert P. Austin, R. Paul Beckett, Michael I. Page	38
19	The Effect of lonic Strength on Liposome–Buffer and 1-Octanol–Buffer Distribution Coefficients 1998 ·Journal of Pharmaceutical Sciences ·Rupert P. Austin, Patrick Barton, A. M. Davis, Carol N. Manners, (unknown)	49
20	Partitioning of Ionizing Molecules between Aqueous Buffers and Phospholipid Vesicles 1995 ·Journal of Pharmaceutical Sciences ·Rupert P. Austin, A. M. Davis, Carol N. Manners	138

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact